Immunotherapy Drugs Market - Global Outlook & Forecast 2021-2026
In-depth Analysis and Data-driven Insights on the Impact of COVID-19 Included in this Global Immunotherapy Drugs Market Report
The global immunotherapy drugs market was valued at USD 169.47 billion in 2020 and is expected to reach USD 326.36 billion by 2026, growing at a CAGR of 11.54%.
The major factor responsible for growth in the immunotherapy drugs industry is an increase in demand for outsourcing the manufacturing of immunotherapy drugs by several biopharmaceuticals and biotechnological companies and resistance against conventional treatments. Major key players and other prominent vendors engaged in the immunotherapy drugs domain are constantly focussing on product launches, product approvals, R&D activities, and expanding their organic growth.
The following factors are likely to contribute to the growth of the global immunotherapy market during the forecast period:
GLOBAL IMMUNOTHERAPY MARKET SEGMENTATION
This research report includes a detailed segmentation by
1. How big is the immunotherapy drugs market?
2. What are the products segmentation in the immunotherapy drugs market?
3. Which region has the highest growth rate for the immunotherapy drugs industry?
4. What are the latest trends in the global immunotherapy drugs market?
5. What is the impact of COVID-19 on the immunotherapy drugs market?
6. Who are the prominent players in the global immunotherapy drugs market?
7. Which countries are the major contributor for Cancer Immunotherapy Drugs Market in APAC?
The global immunotherapy drugs market was valued at USD 169.47 billion in 2020 and is expected to reach USD 326.36 billion by 2026, growing at a CAGR of 11.54%.
The major factor responsible for growth in the immunotherapy drugs industry is an increase in demand for outsourcing the manufacturing of immunotherapy drugs by several biopharmaceuticals and biotechnological companies and resistance against conventional treatments. Major key players and other prominent vendors engaged in the immunotherapy drugs domain are constantly focussing on product launches, product approvals, R&D activities, and expanding their organic growth.
The following factors are likely to contribute to the growth of the global immunotherapy market during the forecast period:
- Next-generation immunotherapies
- COVID-19 as a catalyst
- Investment in research & development activities
- Mergers & acquisitions
- Surge of CAR-T therapies
- The emergence of various diseases in developing countries is propelling the usage of monoclonal antibodies, demanding the introduction of newer immunotherapies and creating opportunities for the market.
- Cancer immunotherapy drugs revolutionized in cancer therapies that have begun to shift curve of cancer patients by increasing their lifespan.
- The increasing immunotherapy drugs pipeline coupled with the emergence of the pandemic has scaled up the production of medicines.
- By product, the adoptive cell therapy segment is expected to witness absolute growth of 1280% during the forecast period.
- The recent trend of mergers and acquisitions is boosting the growth of the immunotherapy drugs industry. For instance, Bristol-Myers Squibb’s one of most recent and high-value transactions was the acquisition of Celgene in January 2018.
GLOBAL IMMUNOTHERAPY MARKET SEGMENTATION
This research report includes a detailed segmentation by
- Product
- Application
- Geography
- The monoclonal antibody segment accounted for the high share of 72.6% of the global immunotherapy drugs market in 2020. Significant advances in the field, notably, and the unprecedented results obtained using monoclonal antibodies that attach themselves to lymphocytes. This restores their functioning toward tumor cell and thus create a defense for the body against cancer.
- The autoimmune diseases segment accounted for the highest market share in 2020. It is expected to post an incremental growth of USD 23.95 billion with 33% absolute growth during the forecast period. The segment's growth is attributed to the increase in the prevalence of immune-mediated inflammatory diseases (IMIDs), including autoimmune and auto-inflammatory diseases.
- In 2020, the cancer segment accounted for the highest market share of 45.33%. Immunotherapies in oncology have been widely popularized by developing curative therapies, such as CAR T-cell. However, developing personalized therapies such as CAR T-cell to treat various types of cancers may pose significant challenges, such as educating medical personnel regarding the procedures and creating a convenient process for engineering T-cells of the patients and infusing them.
- Monoclonal Antibodies
- Immune System Modulators
- Car T-Cell Therapies
- Others
- Cancer
- Auto Immune & Inflammatory Disease
- Others
- North America: North America has the highest share among all the regions and is likely to witness an absolute growth of around 105% during the forecast period. The rise in the immunotherapy drugs industry is primarily attributable to the increasing incidence rates of various types of cancers such as non-Hodgkin lymphoma, Hodgkin lymphoma, melanoma of the skin, and leukemia, etc.
- Europe: Europeans represent about one-tenth of the global population, yet one in four of all cancer diagnoses occur in this region. This region is likely to witness an absolute growth of around 84% during the forecast period.
- APAC: APAC is witnessing growing demand mainly due to a large and growing population. In APAC, various opportunities associated with the growth of the cancer immunotherapy drugs market are increasing, and government initiatives will further improve the healthcare sector.
- North America
- US
- Canada
- Europe
- Germany
- France
- UK
- Italy
- Spain
- APAC
- China
- India
- Japan
- Australia
- South Korea
- Latin America
- Brazil
- Mexico
- Argentina
- Middle East & Africa
- South Africa
- Saudi Arabia
- Turkey
- The major vendors such as F. Hoffmann-La Roche, Bristol Myers Squibb Company, Merck & Co., Inc., GlaxoSmithKline, Novartis, AstraZeneca, and Janssen Pharmaceuticals Inc.
- Bristol Myers Squibb (BMS) is a biopharmaceutical company that is helping – outpatients in succeeding aliments by delivering innovative products. It has owned innovative drugs such as OPDIVO Immunotherapy Drugs for a wider range of diseases.
- Market competitiveness is expected to increase during the forecast period as the vendors constantly focus on expanding their product portfolios.
- F. Hoffmann-La Roche
- Bristol Myers Squibb Company
- Merck & Co., Inc.
- GlaxoSmithKline
- Novartis
- AstraZeneca
- Janssen Pharmaceuticals, Inc.
- AbbVie
- Alexion Pharmaceuticals
- Amgen
- Bayer
- Dendreon
- Dynavax
- Eli Lilly and Company
- Elusys Therapeutics, Inc
- Gilead Sciences, Inc
- NBE Therapeutics
- Pfizer, Inc
- Sanofi
- Seagen Inc.
- Teva pharmaceuticals
1. How big is the immunotherapy drugs market?
2. What are the products segmentation in the immunotherapy drugs market?
3. Which region has the highest growth rate for the immunotherapy drugs industry?
4. What are the latest trends in the global immunotherapy drugs market?
5. What is the impact of COVID-19 on the immunotherapy drugs market?
6. Who are the prominent players in the global immunotherapy drugs market?
7. Which countries are the major contributor for Cancer Immunotherapy Drugs Market in APAC?
1 RESEARCH METHODOLOGY
2 RESEARCH OBJECTIVES
3 RESEARCH PROCESS
4 SCOPE & COVERAGE
4.1 Market Definition
4.1.1 Inclusions
4.1.2 Exclusions
4.1.3 Market Estimation Caveats
4.2 Base Year
4.3 Scope of the Study
4.3.1 Market Segmentation by Geography
4.3.2 Market Segmentation by Product
4.3.3 Market Segmentation by Application
5 REPORT ASSUMPTIONS & CAVEATS
5.1 Key Caveats
5.2 Currency Conversion
5.3 Market Derivation
6 MARKET AT A GLANCE
7 INTRODUCTION
7.1 Overview
8 MARKET OPPORTUNITIES & TRENDS
8.1 Launch of Next-Generation Immunotherapies
8.2 COVID-19 as Growth Catalyst
8.3 Investment in R&D Activities
8.4 Mergers & Acquisitions
9 MARKET GROWTH ENABLERS
9.1 Prevalence of Cancer & Autoimmune Diseases
9.2 Approval of Novel Immunotherapy Drugs
9.3 Surge in Adoption of Car T-Cell Therapies
10 MARKET RESTRAINTS
10.1 Expensive Nature of Immunotherapy
10.2 Personalized Approach Through Biomarkers
10.3 Time-Consuming Production Cycle
11 MARKET LANDSCAPE
11.1 Market Overview
11.2 Market Size & Forecast
11.2.1 Geographic Insights
11.2.2 Application Insights
11.2.3 Product Insights
11.3 Impact of COVID-19 on Immunotherapy Drugs
11.4 Porter’s Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
12 PRODUCT
12.1 Market Snapshot & Growth Engine
12.2 Market Overview
12.3 Monoclonal Antibody
12.3.1 Market Overview
12.3.2 Market Size & Forecast
12.4 Immune System Modulators
12.4.1 Market Overview
12.4.2 Market Size & Forecast
12.5 Car T-Cell Therapy
12.5.1 Market overview
12.5.2 Market Size & Forecast
12.6 Others
12.6.1 Market overview
12.6.2 Market Size & Forecast
13 APPLICATION
13.1 Market Snapshot & Growth Engine
13.2 Market Overview
13.3 Cancer
13.3.1 Market overview
13.3.2 Market Size & Forecast
13.4 Autoimmune & Inflammatory Diseases
13.4.1 Market overview
13.4.2 Market Size & Forecast
13.5 Others
13.5.1 Market overview
13.5.2 Market Size & Forecast
14 GEOGRAPHY
14.1 Market Snapshot & Growth Engine
14.2 Geographic Overview
15 NORTH AMERICA
15.1 Market Overview
15.2 Market Size & Forecast
15.3 Key Countries
15.3.1 US: Market Size & Forecast
15.3.2 Canada: Market Size & Forecast
16 EUROPE
16.1 Market Overview
16.2 Market Size & Forecast
16.3 Key Countries
16.3.1 Germany: Market Size & Forecast
16.3.2 UK: Market Size & Forecast
16.3.3 France: Market Size & Forecast
16.3.4 Italy: Market Size & Forecast
16.3.5 Spain: Market Size & Forecast
17 ASIA PACIFIC
17.1 Market Overview
17.2 Market Size & Forecast
17.3 Key Countries
17.3.1 China: Market Size & Forecast
17.3.2 India: Market Size & Forecast
17.3.3 Japan: Market Size & Forecast
17.3.4 Australia: Market Size & Forecast
17.3.5 South Korea: Market Size & Forecast
18 LATIN AMERICA
18.1 Market Overview
18.2 Market Size & Forecast
18.3 Key Countries
18.3.1 Brazil: Market Size & Forecast
18.3.2 Mexico: Market Size & Forecast
18.3.3 Argentina: Market Size & Forecast
19 MIDDLE EAST & AFRICA
19.1 Market Overview
19.2 Market Size & Forecast
19.3 Key Countries
19.3.1 South Africa: Market Size & Forecast
19.3.2 Saudi Arabia: Market Size & Forecast
19.3.3 Turkey: Market & Forecast
20 COMPETITIVE LANDSCAPE
20.1 Competition Overview
20.2 Market Share Analysis
20.2.1 F. Hoffmann-La Roche AG
20.2.2 Bristol Myers Squibb
20.2.3 Merck & Co., Inc.
20.2.4 GlaxoSmithKline
20.2.5 Novartis
20.2.6 AstraZeneca
20.2.7 Janssen Pharmaceuticals
21 KEY COMPANY PROFILES
21.1 F. Hoffmann-La Roche
21.1.1 Business Overview
21.1.2 Product Offerings
21.1.3 Key Strategies
21.1.4 Key Strengths
21.1.5 Key Opportunities
21.2 Bristol-Myers Squibb Company
21.2.1 Business Overview
21.2.2 Product Offerings
21.2.3 Key Strategies
21.2.4 Key Strengths
21.2.5 Key Opportunities
21.3 Merck & Co., Inc.
21.3.1 Business Overview
21.3.2 Product Offerings
21.3.3 Key Strategies
21.3.4 Key Strengths
21.3.5 Key Opportunities
21.4 GlaxoSmithKline
21.4.1 Business Overview
21.4.2 Product Offerings
21.4.3 Key Strategies
21.4.4 Key Strengths
21.4.5 Key Opportunities
21.5 Novartis
21.5.1 Business Overview
21.5.2 Product Offerings
21.5.3 Key Strategies
21.5.4 Key Strengths
21.5.5 Key Opportunities
21.6 Astrazeneca
21.6.1 Business Overview
21.6.2 Product Offerings
21.6.3 Key Strategies
21.6.4 Key Strengths
21.6.5 Key Opportunities
21.7 Janssen Pharmaceuticals, Inc.
21.7.1 Business Overview
21.7.2 Product Offerings
21.7.3 Key Strategies
21.7.4 Key Strengths
21.7.5 Key Opportunities
22 OTHER PROMINENT VENDORS
22.1 Abbvie
22.1.1 Business Overview
22.1.2 Product Offerings
22.2 Alexion Pharmaceuticals
22.2.1 Business Overview
22.2.2 Product Offerings
22.3 Amgen
22.3.1 Business Overview
22.3.2 Product Offerings
22.4 Bayer
22.4.1 Business Overview
22.4.2 Product Offerings
22.5 Dendreon
22.5.1 Business Overview
22.5.2 Product Offerings
22.6 Dynavax
22.6.1 Business Overview
22.6.2 Product Offerings
22.7 Eli Lilly & Company
22.7.1 Business Overview
22.7.2 Product Offerings
22.8 Elusys Therapeutics, Inc.
22.8.1 Business Overview
22.8.2 Product Offerings
22.9 Gilead Sciences, Inc.
22.9.1 Business Overview
22.9.2 Product Offerings
22.10 NBE Therapeutics
22.10.1 Business Overview
22.11 Pfizer, Inc.
22.11.1 Business Overview
22.11.2 Product Offerings
22.12 Sanofi
22.12.1 Business Overview
22.12.2 Product Offerings
22.13 Seagen Inc.
22.13.1 Business Overview
22.13.2 Product Offerings
22.14 Teva Pharmaceuticals
22.14.1 Business Overview
22.14.2 Product Offerings
23 REPORT SUMMARY
23.1 Key Takeaways
23.2 Strategic Recommendations
24 QUANTITATIVE SUMMARY
24.1 Market by Geography
24.2 Market by Product
24.3 Market by Application
25 APPENDIX
25.1 Abbreviations
2 RESEARCH OBJECTIVES
3 RESEARCH PROCESS
4 SCOPE & COVERAGE
4.1 Market Definition
4.1.1 Inclusions
4.1.2 Exclusions
4.1.3 Market Estimation Caveats
4.2 Base Year
4.3 Scope of the Study
4.3.1 Market Segmentation by Geography
4.3.2 Market Segmentation by Product
4.3.3 Market Segmentation by Application
5 REPORT ASSUMPTIONS & CAVEATS
5.1 Key Caveats
5.2 Currency Conversion
5.3 Market Derivation
6 MARKET AT A GLANCE
7 INTRODUCTION
7.1 Overview
8 MARKET OPPORTUNITIES & TRENDS
8.1 Launch of Next-Generation Immunotherapies
8.2 COVID-19 as Growth Catalyst
8.3 Investment in R&D Activities
8.4 Mergers & Acquisitions
9 MARKET GROWTH ENABLERS
9.1 Prevalence of Cancer & Autoimmune Diseases
9.2 Approval of Novel Immunotherapy Drugs
9.3 Surge in Adoption of Car T-Cell Therapies
10 MARKET RESTRAINTS
10.1 Expensive Nature of Immunotherapy
10.2 Personalized Approach Through Biomarkers
10.3 Time-Consuming Production Cycle
11 MARKET LANDSCAPE
11.1 Market Overview
11.2 Market Size & Forecast
11.2.1 Geographic Insights
11.2.2 Application Insights
11.2.3 Product Insights
11.3 Impact of COVID-19 on Immunotherapy Drugs
11.4 Porter’s Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
12 PRODUCT
12.1 Market Snapshot & Growth Engine
12.2 Market Overview
12.3 Monoclonal Antibody
12.3.1 Market Overview
12.3.2 Market Size & Forecast
12.4 Immune System Modulators
12.4.1 Market Overview
12.4.2 Market Size & Forecast
12.5 Car T-Cell Therapy
12.5.1 Market overview
12.5.2 Market Size & Forecast
12.6 Others
12.6.1 Market overview
12.6.2 Market Size & Forecast
13 APPLICATION
13.1 Market Snapshot & Growth Engine
13.2 Market Overview
13.3 Cancer
13.3.1 Market overview
13.3.2 Market Size & Forecast
13.4 Autoimmune & Inflammatory Diseases
13.4.1 Market overview
13.4.2 Market Size & Forecast
13.5 Others
13.5.1 Market overview
13.5.2 Market Size & Forecast
14 GEOGRAPHY
14.1 Market Snapshot & Growth Engine
14.2 Geographic Overview
15 NORTH AMERICA
15.1 Market Overview
15.2 Market Size & Forecast
15.3 Key Countries
15.3.1 US: Market Size & Forecast
15.3.2 Canada: Market Size & Forecast
16 EUROPE
16.1 Market Overview
16.2 Market Size & Forecast
16.3 Key Countries
16.3.1 Germany: Market Size & Forecast
16.3.2 UK: Market Size & Forecast
16.3.3 France: Market Size & Forecast
16.3.4 Italy: Market Size & Forecast
16.3.5 Spain: Market Size & Forecast
17 ASIA PACIFIC
17.1 Market Overview
17.2 Market Size & Forecast
17.3 Key Countries
17.3.1 China: Market Size & Forecast
17.3.2 India: Market Size & Forecast
17.3.3 Japan: Market Size & Forecast
17.3.4 Australia: Market Size & Forecast
17.3.5 South Korea: Market Size & Forecast
18 LATIN AMERICA
18.1 Market Overview
18.2 Market Size & Forecast
18.3 Key Countries
18.3.1 Brazil: Market Size & Forecast
18.3.2 Mexico: Market Size & Forecast
18.3.3 Argentina: Market Size & Forecast
19 MIDDLE EAST & AFRICA
19.1 Market Overview
19.2 Market Size & Forecast
19.3 Key Countries
19.3.1 South Africa: Market Size & Forecast
19.3.2 Saudi Arabia: Market Size & Forecast
19.3.3 Turkey: Market & Forecast
20 COMPETITIVE LANDSCAPE
20.1 Competition Overview
20.2 Market Share Analysis
20.2.1 F. Hoffmann-La Roche AG
20.2.2 Bristol Myers Squibb
20.2.3 Merck & Co., Inc.
20.2.4 GlaxoSmithKline
20.2.5 Novartis
20.2.6 AstraZeneca
20.2.7 Janssen Pharmaceuticals
21 KEY COMPANY PROFILES
21.1 F. Hoffmann-La Roche
21.1.1 Business Overview
21.1.2 Product Offerings
21.1.3 Key Strategies
21.1.4 Key Strengths
21.1.5 Key Opportunities
21.2 Bristol-Myers Squibb Company
21.2.1 Business Overview
21.2.2 Product Offerings
21.2.3 Key Strategies
21.2.4 Key Strengths
21.2.5 Key Opportunities
21.3 Merck & Co., Inc.
21.3.1 Business Overview
21.3.2 Product Offerings
21.3.3 Key Strategies
21.3.4 Key Strengths
21.3.5 Key Opportunities
21.4 GlaxoSmithKline
21.4.1 Business Overview
21.4.2 Product Offerings
21.4.3 Key Strategies
21.4.4 Key Strengths
21.4.5 Key Opportunities
21.5 Novartis
21.5.1 Business Overview
21.5.2 Product Offerings
21.5.3 Key Strategies
21.5.4 Key Strengths
21.5.5 Key Opportunities
21.6 Astrazeneca
21.6.1 Business Overview
21.6.2 Product Offerings
21.6.3 Key Strategies
21.6.4 Key Strengths
21.6.5 Key Opportunities
21.7 Janssen Pharmaceuticals, Inc.
21.7.1 Business Overview
21.7.2 Product Offerings
21.7.3 Key Strategies
21.7.4 Key Strengths
21.7.5 Key Opportunities
22 OTHER PROMINENT VENDORS
22.1 Abbvie
22.1.1 Business Overview
22.1.2 Product Offerings
22.2 Alexion Pharmaceuticals
22.2.1 Business Overview
22.2.2 Product Offerings
22.3 Amgen
22.3.1 Business Overview
22.3.2 Product Offerings
22.4 Bayer
22.4.1 Business Overview
22.4.2 Product Offerings
22.5 Dendreon
22.5.1 Business Overview
22.5.2 Product Offerings
22.6 Dynavax
22.6.1 Business Overview
22.6.2 Product Offerings
22.7 Eli Lilly & Company
22.7.1 Business Overview
22.7.2 Product Offerings
22.8 Elusys Therapeutics, Inc.
22.8.1 Business Overview
22.8.2 Product Offerings
22.9 Gilead Sciences, Inc.
22.9.1 Business Overview
22.9.2 Product Offerings
22.10 NBE Therapeutics
22.10.1 Business Overview
22.11 Pfizer, Inc.
22.11.1 Business Overview
22.11.2 Product Offerings
22.12 Sanofi
22.12.1 Business Overview
22.12.2 Product Offerings
22.13 Seagen Inc.
22.13.1 Business Overview
22.13.2 Product Offerings
22.14 Teva Pharmaceuticals
22.14.1 Business Overview
22.14.2 Product Offerings
23 REPORT SUMMARY
23.1 Key Takeaways
23.2 Strategic Recommendations
24 QUANTITATIVE SUMMARY
24.1 Market by Geography
24.2 Market by Product
24.3 Market by Application
25 APPENDIX
25.1 Abbreviations
LIST OF EXHIBITS
Exhibit 1 Segmentation of Global Immunotherapy Drugs Market
Exhibit 2 Market Size Calculation Approach 2020
Exhibit 3 Impact of Launch of Next-Generation Immunotherapies
Exhibit 4 Impact of COVID-19 as Growth Catalyst
Exhibit 5 Impact of Investment in R&D Activities
Exhibit 6 Impact of Mergers & Acquisitions
Exhibit 7 Impact of Prevalence of Cancer & Autoimmune Diseases
Exhibit 8 Impact of Approval of Novel Immunotherapy Drugs
Exhibit 9 Impact of Surge in Adoption of CAR T-cell Therapies
Exhibit 10 Number of CAR T-cell Therapies in Clinical Trials (January 2018)
Exhibit 11 Major Vendors Engaged in CAR T-cell Therapy Development
Exhibit 12 Approved CAR T-cell Therapies
Exhibit 13 Impact of Expensive Nature of Immunotherapy
Exhibit 14 Impact of Personalized Approach through Biomarkers
Exhibit 15 Impact of Time-consuming Production Cycle
Exhibit 16 Global Immunotherapy Drugs Market 2020–2026 ($ billion)
Exhibit 17 Five Forces Analysis 2020
Exhibit 18 Incremental Growth by Product Segment 2020 & 2026
Exhibit 19 Global Monoclonal Antibody Market 2020–2026 ($ billion)
Exhibit 20 Global Immunomodulator Market 2020–2026 ($ billion)
Exhibit 21 Global Funding for Development of Cell Therapy 2017–2020 ($ billion)
Exhibit 22 Revenues of Kymriah and Yescarta ($ million)
Exhibit 23 Global CAR T-cell Therapy Market 2020–2026 ($ billion)
Exhibit 24 Global Other Immunotherapy Drugs Market 2020–2026 ($ billion)
Exhibit 25 Incremental Growth by Application Segment 2020 & 2026
Exhibit 26 Number of Products in Clinical Trials in Oncology Application
Exhibit 27 Global Cancer Immunotherapy Drugs Market 2020-2026 ($ billion)
Exhibit 28 Global Autoimmune & Inflammatory Diseases Immunotherapy Drugs Market 2020-2026 ($ billion)
Exhibit 29 Global Other Immunotherapy Applications Market 2020-2026 ($ billion)
Exhibit 30 Incremental Growth by Geography 2020 & 2026
Exhibit 31 New Cancer Cases Reported in North America 2020
Exhibit 32 Market Share of Major Countries in North America
Exhibit 33 North America Immunotherapy Drugs Market 2020–2026 ($ billion)
Exhibit 34 Incremental Growth in North America 2020 & 2026
Exhibit 35 US Immunotherapy Drugs Market 2020–2026 ($ billion)
Exhibit 36 Immunotherapy Drugs Market in Canada 2020–2026 ($ billion)
Exhibit 37 Market Share of Major Countries in Europe
Exhibit 38 Europe Immunotherapy Drugs Market 2020–2026 ($ billion)
Exhibit 39 Incremental Growth in Europe 2020 & 2026
Exhibit 40 Immunotherapy Drugs Market in Germany 2020–2026 ($ billion)
Exhibit 41 Estimated Number of People Living with Cancer by 2030 (million)
Exhibit 42 UK Immunotherapy Drugs Market 2020–2026 ($ billion)
Exhibit 43 Immunotherapy Drugs Market in France 2020–2026 ($ billion)
Exhibit 44 Per Capita Healthcare Expenditure in Italy between 2016 & 2018 ($)
Exhibit 45 Immunotherapy drugs Market in Italy 2020–2026 ($ billion)
Exhibit 46 Immunotherapy Drugs Market in Spain 2020–2026 ($ billion)
Exhibit 47 Market Share of Major Countries in APAC
Exhibit 48 APAC Immunotherapy drugs Market 2020–2026 ($ billion)
Exhibit 49 Incremental Growth in APAC 2020 & 2026
Exhibit 50 Number of new Types of Cancer Cases reported in China (2020)
Exhibit 51 Immunotherapy Drugs Market in China 2020–2026 (billion)
Exhibit 52 Immunotherapy Drugs Market in India 2020–2026 ($ billion)
Exhibit 53 Immunotherapy Drugs Market in Japan 2020–2026 ($ billion)
Exhibit 54 Immunotherapy Drugs Market in Australia 2020–2026 ($ billion)
Exhibit 55 Number of New Types of Cancer Cases Reported in Australia (2020)
Exhibit 56 Number of New Types of Cancers in South Korea (2020)
Exhibit 57 Immunotherapy Drugs Market in South Korea 2020–2026 ($ billion)
Exhibit 58 New Types of Cancer Cases Reported in Latin America (2020)
Exhibit 59 Market Share of Major Countries in Latin America
Exhibit 60 Latin America Immunotherapy Drugs Market 2020–2026 ($ billion)
Exhibit 61 Incremental Growth in Latin America 2020 & 2026
Exhibit 62 Immunotherapy Drugs Market in Brazil 2020–2026 ($ billion)
Exhibit 63 Number of New Types of Cancer Cases Reported in Mexico (2020)
Exhibit 64 Immunotherapy Drugs Market in Mexico 2020–2026 ($ billion)
Exhibit 65 Immunotherapy Drugs Market in Argentina 2020–2026 ($ billion)
Exhibit 66 Market Share of Major countries in MEA
Exhibit 67 MEA Immunotherapy Drugs Market 2020–2026 ($ billion)
Exhibit 68 Incremental Growth in Middle East & Africa 2020 & 2026
Exhibit 69 Cancer Cases in Key Countries across MEA 2020
Exhibit 70 Immunotherapy Drugs Market in South Africa 2020–2026 ($ billion)
Exhibit 71 Immunotherapy Drugs Market in Saudi Arabia 2020–2026 ($ billion)
Exhibit 72 Number of New Cancer Cases Reported in Turkey (2020)
Exhibit 73 Immunotherapy Drugs Market in Turkey 2020–2026 ($ billion)
Exhibit 74 Global Immunotherapy Drugs Market by Product 2020–2026
Exhibit 75 Global Immunotherapy Drugs Market by Application 2020–2026
Exhibit 1 Segmentation of Global Immunotherapy Drugs Market
Exhibit 2 Market Size Calculation Approach 2020
Exhibit 3 Impact of Launch of Next-Generation Immunotherapies
Exhibit 4 Impact of COVID-19 as Growth Catalyst
Exhibit 5 Impact of Investment in R&D Activities
Exhibit 6 Impact of Mergers & Acquisitions
Exhibit 7 Impact of Prevalence of Cancer & Autoimmune Diseases
Exhibit 8 Impact of Approval of Novel Immunotherapy Drugs
Exhibit 9 Impact of Surge in Adoption of CAR T-cell Therapies
Exhibit 10 Number of CAR T-cell Therapies in Clinical Trials (January 2018)
Exhibit 11 Major Vendors Engaged in CAR T-cell Therapy Development
Exhibit 12 Approved CAR T-cell Therapies
Exhibit 13 Impact of Expensive Nature of Immunotherapy
Exhibit 14 Impact of Personalized Approach through Biomarkers
Exhibit 15 Impact of Time-consuming Production Cycle
Exhibit 16 Global Immunotherapy Drugs Market 2020–2026 ($ billion)
Exhibit 17 Five Forces Analysis 2020
Exhibit 18 Incremental Growth by Product Segment 2020 & 2026
Exhibit 19 Global Monoclonal Antibody Market 2020–2026 ($ billion)
Exhibit 20 Global Immunomodulator Market 2020–2026 ($ billion)
Exhibit 21 Global Funding for Development of Cell Therapy 2017–2020 ($ billion)
Exhibit 22 Revenues of Kymriah and Yescarta ($ million)
Exhibit 23 Global CAR T-cell Therapy Market 2020–2026 ($ billion)
Exhibit 24 Global Other Immunotherapy Drugs Market 2020–2026 ($ billion)
Exhibit 25 Incremental Growth by Application Segment 2020 & 2026
Exhibit 26 Number of Products in Clinical Trials in Oncology Application
Exhibit 27 Global Cancer Immunotherapy Drugs Market 2020-2026 ($ billion)
Exhibit 28 Global Autoimmune & Inflammatory Diseases Immunotherapy Drugs Market 2020-2026 ($ billion)
Exhibit 29 Global Other Immunotherapy Applications Market 2020-2026 ($ billion)
Exhibit 30 Incremental Growth by Geography 2020 & 2026
Exhibit 31 New Cancer Cases Reported in North America 2020
Exhibit 32 Market Share of Major Countries in North America
Exhibit 33 North America Immunotherapy Drugs Market 2020–2026 ($ billion)
Exhibit 34 Incremental Growth in North America 2020 & 2026
Exhibit 35 US Immunotherapy Drugs Market 2020–2026 ($ billion)
Exhibit 36 Immunotherapy Drugs Market in Canada 2020–2026 ($ billion)
Exhibit 37 Market Share of Major Countries in Europe
Exhibit 38 Europe Immunotherapy Drugs Market 2020–2026 ($ billion)
Exhibit 39 Incremental Growth in Europe 2020 & 2026
Exhibit 40 Immunotherapy Drugs Market in Germany 2020–2026 ($ billion)
Exhibit 41 Estimated Number of People Living with Cancer by 2030 (million)
Exhibit 42 UK Immunotherapy Drugs Market 2020–2026 ($ billion)
Exhibit 43 Immunotherapy Drugs Market in France 2020–2026 ($ billion)
Exhibit 44 Per Capita Healthcare Expenditure in Italy between 2016 & 2018 ($)
Exhibit 45 Immunotherapy drugs Market in Italy 2020–2026 ($ billion)
Exhibit 46 Immunotherapy Drugs Market in Spain 2020–2026 ($ billion)
Exhibit 47 Market Share of Major Countries in APAC
Exhibit 48 APAC Immunotherapy drugs Market 2020–2026 ($ billion)
Exhibit 49 Incremental Growth in APAC 2020 & 2026
Exhibit 50 Number of new Types of Cancer Cases reported in China (2020)
Exhibit 51 Immunotherapy Drugs Market in China 2020–2026 (billion)
Exhibit 52 Immunotherapy Drugs Market in India 2020–2026 ($ billion)
Exhibit 53 Immunotherapy Drugs Market in Japan 2020–2026 ($ billion)
Exhibit 54 Immunotherapy Drugs Market in Australia 2020–2026 ($ billion)
Exhibit 55 Number of New Types of Cancer Cases Reported in Australia (2020)
Exhibit 56 Number of New Types of Cancers in South Korea (2020)
Exhibit 57 Immunotherapy Drugs Market in South Korea 2020–2026 ($ billion)
Exhibit 58 New Types of Cancer Cases Reported in Latin America (2020)
Exhibit 59 Market Share of Major Countries in Latin America
Exhibit 60 Latin America Immunotherapy Drugs Market 2020–2026 ($ billion)
Exhibit 61 Incremental Growth in Latin America 2020 & 2026
Exhibit 62 Immunotherapy Drugs Market in Brazil 2020–2026 ($ billion)
Exhibit 63 Number of New Types of Cancer Cases Reported in Mexico (2020)
Exhibit 64 Immunotherapy Drugs Market in Mexico 2020–2026 ($ billion)
Exhibit 65 Immunotherapy Drugs Market in Argentina 2020–2026 ($ billion)
Exhibit 66 Market Share of Major countries in MEA
Exhibit 67 MEA Immunotherapy Drugs Market 2020–2026 ($ billion)
Exhibit 68 Incremental Growth in Middle East & Africa 2020 & 2026
Exhibit 69 Cancer Cases in Key Countries across MEA 2020
Exhibit 70 Immunotherapy Drugs Market in South Africa 2020–2026 ($ billion)
Exhibit 71 Immunotherapy Drugs Market in Saudi Arabia 2020–2026 ($ billion)
Exhibit 72 Number of New Cancer Cases Reported in Turkey (2020)
Exhibit 73 Immunotherapy Drugs Market in Turkey 2020–2026 ($ billion)
Exhibit 74 Global Immunotherapy Drugs Market by Product 2020–2026
Exhibit 75 Global Immunotherapy Drugs Market by Application 2020–2026
LIST OF TABLES
Table 1 Key Caveats
Table 2 Currency Conversion 2013–2020
Table 3 Major Mergers & Acquisitions
Table 4 Major Approved Immunotherapy Drugs
Table 5 CAR T-cell Investigational Products
Table 6 Cost of Kymriah in Different Regions
Table 7 CAGR & Revenue of Approved CAR T-cell Therapies 2018–2020 ($ million)
Table 8 CAGR & Revenue of Other Approved Therapies 2018–2020 ($ million)
Table 9 CAR-T Therapies Approved in Japan Region
Table 10 F. Hoffmann-La Roche: Major Product Offerings
Table 11 Bristol Myers Squibb: Major Product Offerings
Table 12 Merck & Co., Inc.: Major Product Offerings
Table 13 GlaxoSmithKline: Major Product Offerings
Table 14 Novartis: Major Product Offerings
Table 15 AstraZeneca: Major Product Offerings
Table 16 Janssen Pharmaceuticals, Inc.: Major Product Offerings
Table 17 AbbVie: Major Product Offerings
Table 18 Alexion Pharmaceuticals: Major Product Offerings
Table 19 Amgen: Major Product Offerings
Table 20 Bayer: Major Product Offerings
Table 21 Dendreon: Major Product Offerings
Table 22 Dynavax: Major Product Offerings
Table 23 Eli Lilly & Company: Major Product Offerings
Table 24 Elusys Therapeutics, Inc.: Major Product Offerings
Table 25 Gilead Sciences, Inc.: Major Product Offerings
Table 26 Pfizer, Inc.: Major Product Offerings
Table 27 Sanofi: Major Product Offerings
Table 28 Seagen Inc.: Major Product Offerings
Table 29 Teva Pharmaceuticals: Major Product Offerings
Table 30 Global Immunotherapy Drugs Market by 2020–2026 ($ billion) (Geography)
Table 31 North America Immunotherapy Drugs Market 2020–2026 (%)
Table 32 Europe Immunotherapy Drugs Market 2020–2026 (%)
Table 33 APAC Immunotherapy Drugs Market 2020–2026 (%)
Table 34 Latin America Immunotherapy Drugs Market 2020–2026 (%)
Table 35 MEA Immunotherapy Drugs Market 2020–2026 (%)
Table 1 Key Caveats
Table 2 Currency Conversion 2013–2020
Table 3 Major Mergers & Acquisitions
Table 4 Major Approved Immunotherapy Drugs
Table 5 CAR T-cell Investigational Products
Table 6 Cost of Kymriah in Different Regions
Table 7 CAGR & Revenue of Approved CAR T-cell Therapies 2018–2020 ($ million)
Table 8 CAGR & Revenue of Other Approved Therapies 2018–2020 ($ million)
Table 9 CAR-T Therapies Approved in Japan Region
Table 10 F. Hoffmann-La Roche: Major Product Offerings
Table 11 Bristol Myers Squibb: Major Product Offerings
Table 12 Merck & Co., Inc.: Major Product Offerings
Table 13 GlaxoSmithKline: Major Product Offerings
Table 14 Novartis: Major Product Offerings
Table 15 AstraZeneca: Major Product Offerings
Table 16 Janssen Pharmaceuticals, Inc.: Major Product Offerings
Table 17 AbbVie: Major Product Offerings
Table 18 Alexion Pharmaceuticals: Major Product Offerings
Table 19 Amgen: Major Product Offerings
Table 20 Bayer: Major Product Offerings
Table 21 Dendreon: Major Product Offerings
Table 22 Dynavax: Major Product Offerings
Table 23 Eli Lilly & Company: Major Product Offerings
Table 24 Elusys Therapeutics, Inc.: Major Product Offerings
Table 25 Gilead Sciences, Inc.: Major Product Offerings
Table 26 Pfizer, Inc.: Major Product Offerings
Table 27 Sanofi: Major Product Offerings
Table 28 Seagen Inc.: Major Product Offerings
Table 29 Teva Pharmaceuticals: Major Product Offerings
Table 30 Global Immunotherapy Drugs Market by 2020–2026 ($ billion) (Geography)
Table 31 North America Immunotherapy Drugs Market 2020–2026 (%)
Table 32 Europe Immunotherapy Drugs Market 2020–2026 (%)
Table 33 APAC Immunotherapy Drugs Market 2020–2026 (%)
Table 34 Latin America Immunotherapy Drugs Market 2020–2026 (%)
Table 35 MEA Immunotherapy Drugs Market 2020–2026 (%)
